NEWS
Eli Lilly & Company in the IMPRESS study
Eli Lilly & Company is now part of the national Norwegian IMPRESS study.
Lite satsing på kreftinnovasjon
Statsbudsjettet for 2022 inneholder lite for kreftpasienter og innovasjon innen kreftbehandling.
Brett Jordan/ UnsplashOur role as Changemaker
Did you know that Oslo Cancer Cluster is a changemaker?
Clay Banks / UnsplashNOK 16 million to new RWE company
The Research Council of Norway recently awarded grants to several innovation projects in the industrial sector. One of the lucky companies was the newcomer NordicRWE.
The Future of Cancer Treatment
For six years we have hosted The Future of Cancer Treatment (Fremtidens kreftbehandling) with the same partners. What is this seminar series all about?
OUSBjørn Atle Bjørnbeth joins the board
Dr. Bjørn Atle Bjørnbeth joined the board of Oslo Cancer Cluster during the annual general meeting.
Nye kreftbehandlinger krever nye samarbeidsformer
Debattinnlegg: Innføring av nye legemidler for små pasientgrupper tar unødvendig lang tid. Noen blir ikke tatt i bruk i Norge i det hele tatt. Det er en utfordring, skriver artikkelforfatterne.
LINK MedicalLinking with the community
We want to highlight the fruitful collaborations in the cluster. In a new article series, we present members who have a cluster story to tell. This week, we meet LINK Medical.
NovartisNovartis enters IMPRESS
Novartis joins the IMPRESS oncology study with six of its cancer medicines to treat up to one hundred patients.
